News & Presentations

News Releases

Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
May 01, 2024
Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon
Apr 23, 2024
Tarsus to Participate at Upcoming Investor Conferences
Mar 05, 2024
Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis
Mar 05, 2024
Tarsus Announces Pricing of $100.0 Million Public Offering
Mar 01, 2024
Tarsus Announces Proposed $100.0 Million Public Offering
Feb 29, 2024
Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements
Feb 27, 2024
Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease
Feb 22, 2024
Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024
Feb 20, 2024
Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference
Jan 31, 2024

Upcoming Events

Tarsus Q1 2024 Earnings Call
May 08, 2024 at 4:30 PM EDT
View Webcast
Add to Outlook
Add to Google Calendar

Presentations